Kamada Ltd. (KMDA) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Kamada Ltd. (KMDA) closed at USD 7.60 on 2026-10-14, a change of +15 % over the past year, with a market capitalization of USD 451.87M.

Kamada Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kamada Ltd. key figures

Previous close

USD 7.60 (2026-10-14)

1-year change

+15 %

Market cap

USD 451.87M

Enterprise value

USD 394.93M

P/E ratio (trailing)

20.61

P/E ratio (forward)

13.58

EPS (trailing)

0.38

EPS (forward)

0.58

PEG ratio

0.57

Price to book

1.68

Revenue growth

22.7 %

Earnings growth

23.1 %

Dividend per share (trailing)

0.25

Short ratio

1.46

Employees

462

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kamada Ltd.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kamada Ltd. and compare it with other stocks.